Skip to content
Research Article Open access CC BY 4.0

A Comprehensive Review on Cancer Immunotherapy in Veterinary Medicine

Shimaakhtar Saiyad, B. B. Bhanderi, P. G. Koringa, R. A. Mathakiya, V. R. Nimavat

International Journal of Biochemistry Research & Review · pp. 47–62 · Published 19 Apr 2024

10.9734/ijbcrr/2024/v33i5875

Abstract

According to a World Health Organization (WHO) estimate, cancer is one of the leading causes of mortality worldwide, expected to claim the lives of almost 10 million people in 2020. It is estimated that 30% of cancer incidences in low- and lower-middle-income countries are caused by diseases like hepatitis and HPV. Many tumours are treatable if detected early and treated properly. The most common malignancies in dogs include transmissible venereal tumours, mammary gland tumours (breast cancer), spleen cancer, skin cancer, lymphatic cancer, gum tumours (epulis cancer), and eye cancer. The frequency of canine cancer cases in India has been rising quickly.   The fast-developing fields of cancer immunology and immunotherapy have revolutionized how cancer is seen and treated. The process of immunotherapy involves using the body's immune system to locate and destroy cancer cells. New immunotherapy medications that selectively target cancer cells while sparing healthy cells have been developed as a result of advancements in immunology. The present study reviews the cause, impacts and effects of Cancer along with the feasibility of Immunotherapy as a cure for the cancer. Checkpoint inhibitors, monoclonal antibodies, vaccinations, and adoptive cell therapy are a few types of immunotherapies. To more effectively target these malignancies, researchers are exploring novel immunotherapy techniques such as oncolytic virotherapy or CAR T-cell treatment. Researchers are working to develop biomarkers to identify which patients would benefit most from immunotherapy. Different immunotherapies have been used by veterinary medicine researchers to treat canine neoplasms. These include the use of "caninized" mAb against canine PD-L1 in dogs that have metastatic melanoma, IL-12 electrogene treatment for mast cell tumours in dogs, and hTyr-specific T cells for stage II and III melanoma. This review discusses several immunotherapy approaches for cancer and their outcomes.

Cancer CAR T-cell dog immunology immunotherapy

References (40)

  1. 1 The biology of human natural killer-cell subsets [DOI]
  2. 2 CAR-T cell therapy: current limitations and potential strategies [DOI]
  3. 3 Immune Checkpoint Inhibitors in Cancer Therapy [DOI]
  4. 4 TIM3 comes of age as an inhibitory receptor [DOI]
  5. 5 Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends [DOI]
  6. 6 Antibody Therapeutics in Cancer [DOI]
  7. 7 Design and development of therapies using chimeric antigen receptor‐expressing T cells [DOI]
  8. 8 Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study [DOI]
  9. 9 The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment [DOI]
  10. 10 Oncolytic virotherapy: basic principles, recent advances and future directions [DOI]
  11. 11 Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
  12. 12 Pembrolizumab: First Global Approval [DOI]
  13. 13 Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment [DOI]
  14. 14 Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies [DOI]
  15. 15 Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer [DOI]
  16. 16 Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells [DOI]
  17. 17 Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies [DOI]
  18. 18 Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level [DOI]
  19. 19 Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation [DOI]
  20. 20 CTLA-4 Blockade Enhances Antitumor Immunity of Intratumoral Injection of Immature Dendritic Cells into Irradiated Tumor in a Mouse Colon Cancer Model [DOI]
  21. 21 Cancer immunotherapy in veterinary medicine: Current options and new developments [DOI]
  22. 22 The effects of age and systemic metabolism on anti-tumor T cell responses [DOI]
  23. 23 Electrogene therapy with interleukin-12 in canine mast cell tumors [DOI]
  24. 24 Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs [DOI]
  25. 25 Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
  26. 26 Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma [DOI]
  27. 27 BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia [DOI]
  28. 28 Targeted biopharmaceuticals for cancer treatment [DOI]
  29. 29 Future prospects of monoclonal antibodies as magic bullets in Immunotherapy [DOI]
  30. 30 Targeted cancer immunotherapy [DOI]
  31. 31 Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs [DOI]
  32. 32 Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice [DOI]
  33. 33 BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia [DOI]
  34. 34 A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas [DOI]
  35. 35 Vaccines and Immunotherapeutics for the Treatment of Malignant Disease [DOI]
  36. 36 Design and development of therapies using chimeric antigen receptor-expressing T cells [DOI]
  37. 37 Developing T Cell Cancer Immunotherapy in the Dog with Lymphoma [DOI]
  38. 38 Nobel Prize in Physiology or Medicine – 2018 [DOI]
  39. 39 Cell Cycle Checkpoints [DOI]
  40. 40 A Role for CTLA‐4‐Mediated Inhibitory Signals in Peripheral T Cell Tolerance? [DOI]

Cited by 2

From Human to Veterinary Medicine: Expanding the Role of Microneedle Drug Delivery and Diagnostic Systems

Kornicka Justyna, Śniadek Patrycja, Walczak Rafał · Advanced Materials & Technologies · 2026

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

44

Page views

0

PDF downloads

5

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.